Meeting
2014 ASCO Annual Meeting
Boosting of cellular and humoral immune responses to HPV16/18 antigens by VGX-3100: A follow-on phase I trial.
Authors
Matthew P Morrow
Inovio Pharmaceuticals, Blue Bell, PA
Matthew P Morrow , Kimberly Kraynyak , Xuefei Shen , Christine Knott , Jian Yan , Kate Broderick , Amir Khan , Mary Giffear , Jessica Lee , Jean Boyer , David Weiner , Niranjan Sardesai , Mark Bagarazzi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Immunotherapy
Track
Developmental Therapeutics
Sub Track
Vaccines
Clinical Trial Registration Number
NCT01188850
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 3101)
DOI
10.1200/jco.2014.32.15_suppl.3101
Abstract #
3101
Poster Bd #
168
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
A phase I study in patients with a human papillomavirus type 16 positive oropharyngeal tumor treated with second generation synthetic long peptide vaccine conjugated to a defined adjuvant.
First Author: Marije Slingerland
Poster
2023 ASCO Annual Meeting
A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer.
First Author: Christine H. Chung
Poster
2023 ASCO Annual Meeting
Introduction of E-Score: A gene expression score to characterize immunogenic versus oncogenic HPV expression in HNSCC.
First Author: Bailey Fabiny Garb
Poster
2022 ASCO Annual Meeting
A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer.
First Author: Christine H. Chung